HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives.
Wang, G., Lei, H., Wang, X., Das, D., Hong, J., Mackinnon, C.H., Coulter, T.S., Montalbetti, C.A., Mears, R., Gai, X., Bailey, S.E., Ruhrmund, D., Hooi, L., Misialek, S., Rajagopalan, P.T., Cheng, R.K., Barker, J.J., Felicetti, B., Schonfeld, D.L., Stoycheva, A., Buckman, B.O., Kossen, K., Seiwert, S.D., Beigelman, L.(2009) Bioorg Med Chem Lett 19: 4480-4483
- PubMed: 19500983
- DOI: https://doi.org/10.1016/j.bmcl.2009.05.022
- Primary Citation of Related Structures:
3H98 - PubMed Abstract:
(1,1-Dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives have been investigated as potential anti-HCV drugs. Their synthesis, HCV NS5B polymerase inhibition, and replicon activity are discussed.
Organizational Affiliation:
Discovery Research, InterMune, Inc., Brisbane, CA 94005, USA. gyiwang@yahoo.com